Small Molecule of the Year – 2021 - Drug Hunter
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers | Request PDF
IJMS | Free Full-Text | Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers | HTML
H3 Biomedicine Publishes Comprehensive Genomic Landscape Analysis in Cell Reports Revealing Breadth, Frequency and Potential Disease-Driving Significance of Somatic Mutations in RNA Splicing Factor Genes in Multiple Types of Cancer | Business
A Comprehensive Overview of Structure‐Activity Relationships of Small‐Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents - Zhang - 2020 - ChemMedChem - Wiley Online Library
RVT-2001 / Eisai, Roivant
Tweets with replies by Dan Wiseman (@dwiseman78) / Twitter
![PDF] Aberrant RNA Splicing in Cancer and Drug Resistance | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1e455e23cd18162830fba4eeb550aac99b08417d/12-Figure5-1.png "PDF] Aberrant RNA Splicing in Cancer and Drug Resistance | Semantic Scholar")
PDF] Aberrant RNA Splicing in Cancer and Drug Resistance | Semantic Scholar
Spliceostatin A interaction with SF3B limits U1 snRNP availability and causes premature cleavage and polyadenylation - ScienceDirect
Eisai out-licenses cancer candidate H3B-8800 to Roivant
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia | Leukemia
Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience. - Abstract - Europe PMC
Reprogramming RNA processing: an emerging therapeutic landscape: Trends in Pharmacological Sciences
Scalable Synthesis of 17S-FD-895 Expands the Structural Understanding of Splice Modulatory Activity - ScienceDirect
Cancers | Free Full-Text | Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features | HTML
Splicing modulators: on the way from nature to clinic | The Journal of Antibiotics
H3B-8800 pharmacokinetics Plasma concentration in ng/mL of H3B-8800 on... | Download Scientific Diagram
Production of novel pladienolide analogues through native expression of a pathway-specific activator - Chemical Science (RSC Publishing) DOI:10.1039/D0SC01928C
FDA accepts H3 Biomedicine's IND application to start phase 1 trials for oncology drug candidate H3B-8800 | Global Pharma Update
H3B-8800 | Chemistry Information PDF | PharmaCompass.com
H3B-8800 modulates splicing and selectively kills SF3B1-mutant leukemia... | Download Scientific Diagram
Selected novel agents in clinical trials for lower-risk MDS Several... | Download Scientific Diagram
Therapeutic approaches to treat human spliceosomal diseases. - Abstract - Europe PMC
Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results | VJHemOnc
